med-reference
Use when correcting a medical or pharmacological misconception, looking up a half-life, dose-response, likelihood-ratio, trial or epidemiological figure, finding the sources, or needing a quick-reference picker — plus the current state of incretin therapeutics and antimicrobial resistance. Companion to the other medicine and pharmacology skills.
- License 许可
- MIT
- 最近更新
- 2026-11-15
- Stars
- ★ 5
- Forks
- 3
01 前言 Front Matter
- name
- med-reference
- description
- Use when correcting a medical or pharmacological misconception, looking up a half-life, dose-response, likelihood-ratio, trial or epidemiological figure, finding the sources, or needing a quick-reference picker — plus the current state of incretin therapeutics and antimicrobial resistance. Companion to the other medicine and pharmacology skills.
03 SKILL.md 正文
Medicine and Pharmacology: What's Live, Misconceptions, Numbers and Concepts, and Sources
Part 6 of 6 of the Fundamentals of Medicine and Pharmacology reference (plugin
medicine-and-pharmacology-fundamentals), covering §27–§32. Sibling skills:med-reading-the-field-physiology-and-clinical-reasoning(§0–§6),med-pharmacokinetics-pharmacodynamics-and-interactions(§7–§12),med-drug-classes-cardiovascular-anti-infective-and-analgesia(§13–§15),med-drug-classes-neuro-endocrine-immunology-and-oncology(§16–§19),med-evidence-trials-safety-screening-and-ethics(§20–§26). Section numbers are shared across the set; a reference written as §N →skillpoints into that sibling skill.Currency: The physiology and pharmacology are stable. Two areas are moving fast. See §27 for incretin therapeutics, and antimicrobial resistance.
⚠️ NOT MEDICAL ADVICE, and this matters more here than in any other file in this series. ⚠️ Nothing here is a diagnosis, a treatment recommendation, or dosing guidance. Individual clinical decisions require a licensed clinician who knows your history, and no general reference substitutes for that.
⚠️ This is pitched where a preclinical survey or an informed-patient reference sits: the concepts that let you understand what medicine is doing and evaluate claims about it. ⚠️ It deliberately contains no dosing tables, no specific regimens, and no operational detail.
Complements an organic-chemistry reference (drug molecules and metabolism), a statistics-adjacent reference (trial methodology), and a speaking-and-influence reference (§20 →
med-evidence-trials-safety-screening-and-ethics's evidence-quality reasoning is the same skill).⚠️ GOTCHA boxes mark where clinical intuition — including clinicians' intuition — is reliably wrong.
The three ideas that organize this document:
- ⚠️ A TEST RESULT IS NOT A DIAGNOSIS (§6 →
med-reading-the-field-physiology-and-clinical-reasoning). The probability that a positive test means disease depends on how likely disease was beforehand. This single Bayesian fact is the most useful thing in clinical medicine and the most consistently misunderstood by patients and clinicians alike.- ⚠️ EVERY DRUG IS A POISON AT SOME DOSE, AND EVERY EFFECT HAS A COST (§9 →
med-pharmacokinetics-pharmacodynamics-and-interactions, §12 →med-pharmacokinetics-pharmacodynamics-and-interactions). There are no side effects — only effects, some of which you wanted. The therapeutic question is always a ratio, never an absolute.- ⚠️ MOST OF WHAT DETERMINES HEALTH HAPPENS OUTSIDE CLINICAL MEDICINE (§25 →
med-evidence-trials-safety-screening-and-ethics). Sanitation, nutrition, income, housing and vaccination did more for life expectancy than the entire therapeutic pharmacopoeia, and clinical medicine's share of health outcomes is smaller than its share of spending.
§27. What's Live — checked August 2026
27.1 ⚠️ Incretin therapeutics: a class that outgrew its indication
⚠️ §17 → med-drug-classes-neuro-endocrine-immunology-and-oncology's area being reshaped, and it is the clearest current illustration of §20 → med-evidence-trials-safety-screening-and-ethics's
surrogate-versus-outcome distinction working in the right direction.
- ⚠️ THE EFFICACY STAIRCASE, as summarized in the trade and academic literature: ⚠️ semaglutide, a single GLP-1 receptor agonist, established roughly 15% average weight loss in pivotal obesity trials; tirzepatide, adding GIP receptor agonism, raised that to around 21%; and triple agonists in development are reported above 28%.
- ⚠️ ORAL FORMULATIONS ARRIVED. ⚠️ Two pivotal phase 3 trials were published in
September 2025: ATTAIN-1 evaluated orforglipron in 3,127 adults over 72 weeks with mean
weight loss of 11.2%, and OASIS-4 studied oral semaglutide 25 mg in 307 adults over 64
weeks with mean weight loss of 13.6%. ⚠️ An oral semaglutide product for weight
management became available in January 2026.
⚠️ The formulation problem is genuinely interesting pharmacology (§7 →
med-pharmacokinetics-pharmacodynamics-and-interactions): semaglutide is a large peptide, and oral delivery uses an absorption enhancer to get it across the gut wall at all. - ⚠️ THE INDICATIONS EXPANDED BEYOND WEIGHT AND GLUCOSE, which is the substantive point. ⚠️ In the phase 3 ESSENCE trial, semaglutide produced resolution of steatohepatitis without worsening fibrosis in 62.9% of patients with biopsy-confirmed MASH versus 34.3% with placebo, with FDA accelerated approval for that indication in August 2025. ⚠️ Reported cardiovascular benefits include a 14% reduction in major adverse cardiovascular events. ⚠️ Knee osteoarthritis pain outcomes also improved.
⚠️ GOTCHA — this is a class where the honest caveats are as important as the headlines. ⚠️ The trials are largely industry-sponsored (§21 →
med-evidence-trials-safety-screening-and-ethics), and much accessible coverage comes from pharmacy benefit managers, prescription-discount companies and conference reporting rather than from independent analysis. ⚠️ Gastrointestinal adverse events are consistent across the class; the oral trials reported five mild pancreatitis cases with orforglipron and dysesthesia with oral semaglutide. ⚠️ Longer-term safety follows §12 →med-pharmacokinetics-pharmacodynamics-and-interactions's rule — a class this new, used this widely, will have its full profile characterized only in post-marketing surveillance. ⚠️ Lean body mass preservation, durability after discontinuation, cost and access remain genuinely open questions, ⚠️ and one review notes GLP-1 use in the US rose roughly 700% over four years to 2023, which is an adoption curve outpacing the long-term evidence.
⚠️ Why it matters conceptually: ⚠️ these agents are increasingly chosen for OUTCOME
benefits — cardiovascular events, liver histology — rather than for the surrogate they were
designed to move. ⚠️ That is §20 → med-evidence-trials-safety-screening-and-ethics's distinction operating correctly, and it is rarer than
it should be.
27.2 ⚠️ Antimicrobial resistance: the problem that gets worse while nothing happens
⚠️ §14 → med-drug-classes-cardiovascular-anti-infective-and-analgesia's structural problem, and the sharpest contrast with §27.1 in this file.
- ⚠️ THE SCALE. ⚠️ WHO states that approximately 1 in 6 laboratory-confirmed bacterial infections worldwide were resistant to antibiotics in 2023. ⚠️ The 2025 GLASS report drew on more than 23 million bacteriologically confirmed cases reported by 104 countries, providing estimates across 93 infection-pathogen-antibiotic combinations and tracking trends for 16 of them from 2018 to 2023.
- ⚠️ Gram-negative organisms are the acute concern, with rising resistance to carbapenems and fluoroquinolones — and low- and middle-income countries bear a higher burden through weaker health systems and limited diagnostic capacity.
- ⚠️ WHO'S OWN CHARACTERIZATION IS BLUNT: ⚠️ "the world faces an antimicrobial research and development crisis, with few new medicines in the pipeline." ⚠️ The Global Action Plan on AMR has been updated for 2026–2036.
- ⚠️ THE PIPELINE ASSESSMENT. ⚠️ The Access to Medicine Foundation's 2026 AMR Benchmark, reviewing 25 companies, found continued CONTRACTION among the seven large research-based companies, with small and medium enterprises driving innovation for critical- and high-priority pathogens. ⚠️ Its overall conclusion is that industry-wide efforts "are being outpaced by drug resistance."
⚠️ GOTCHA — this is a MARKET FAILURE, not a science failure, and the economics are perverse in a specific way. ⚠️ A successful new antibiotic should be used as little as possible and reserved for resistant infections (§14 →
med-drug-classes-cardiovascular-anti-infective-and-analgesia's stewardship) — which means the better it is, the less revenue it generates. ⚠️ No other drug class has that property, and it is why conventional market incentives cannot fund antibiotic development. ⚠️ The consequences are visible in the reporting: a company terminating its sole pipeline project and dropping out of the benchmark entirely, and analysis noting expected pipeline decline as late-stage funding tapers. ⚠️ There is also a substantive critique that pipeline expansion alone is not the answer — ⚠️ infectious disease specialists quoted argue that producing more drugs within the same class does little for genuinely resistant organisms, and that innovation has been "predominantly incremental," built on old scaffolds rather than novel mechanisms.
⚠️ What is actually being tried: ⚠️ WHO published new target product profiles in March
2026 defining minimum and preferred characteristics for urgently needed antibacterials;
⚠️ pull incentives such as market entry rewards and subscription models attempt to decouple
revenue from volume; ⚠️ and alternative modalities — phage therapy, antimicrobial peptides,
CRISPR-based approaches — are under investigation with real translational obstacles.
⚠️ And the unglamorous interventions remain the highest-value ones: ⚠️ infection
prevention, vaccination, diagnostics that let clinicians avoid empirical broad-spectrum
treatment, surveillance, and stewardship (§14 → med-drug-classes-cardiovascular-anti-infective-and-analgesia, §25 → med-evidence-trials-safety-screening-and-ethics).
⚠️ Sourcing note: this section rests on WHO's own fact sheet and GLASS report and on the
Access to Medicine Foundation benchmark — the latter being an independent nonprofit rather
than an industry body, which is why I have used its pipeline assessment.
§28. Misconceptions
| Misconception | Correction |
|---|---|
| A positive test means you have it | ⚠️ Depends on pre-test probability. Often it doesn't (§6 → med-reading-the-field-physiology-and-clinical-reasoning) |
| A very accurate test is reliable in screening | ⚠️ Low prevalence swamps it with false positives (§6 → med-reading-the-field-physiology-and-clinical-reasoning, §24 → med-evidence-trials-safety-screening-and-ethics) |
| Sensitivity tells you what a positive means | ⚠️ That's PPV, and it depends on prevalence (§6 → med-reading-the-field-physiology-and-clinical-reasoning) |
| Diagnosis comes from tests | ⚠️ Mostly from the history (§5 → med-reading-the-field-physiology-and-clinical-reasoning) |
| Feeling fine means healthy | ⚠️ Organ reserve masks substantial damage (§2 → med-reading-the-field-physiology-and-clinical-reasoning) |
| Side effects are a separate category | ⚠️ They're just effects you didn't want (§12 → med-pharmacokinetics-pharmacodynamics-and-interactions) |
| Natural products don't interact | ⚠️ St John's wort induces CYP enzymes potently (§10 → med-pharmacokinetics-pharmacodynamics-and-interactions) |
| A more potent drug is a better drug | ⚠️ Potency is dose, not effect. Different axis (§9 → med-pharmacokinetics-pharmacodynamics-and-interactions) |
| Half-life tells you when it's gone | ⚠️ ~4–5 half-lives to steady state and to washout (§7 → med-pharmacokinetics-pharmacodynamics-and-interactions) |
| Oral and IV doses should match | ⚠️ First-pass metabolism (§7 → med-pharmacokinetics-pharmacodynamics-and-interactions) |
| Physical dependence is addiction | ⚠️ Three different things. Conflating harms both ways (§15 → med-drug-classes-cardiovascular-anti-infective-and-analgesia) |
| Stopping a drug is always safe | ⚠️ Receptor upregulation causes rebound. Some need tapering (§8 → med-pharmacokinetics-pharmacodynamics-and-interactions, §16 → med-drug-classes-neuro-endocrine-immunology-and-oncology) |
| Antibiotics help with a bad cold | ⚠️ Viral. No benefit, and drives resistance (§14 → med-drug-classes-cardiovascular-anti-infective-and-analgesia) |
| Always finish the antibiotic course | ⚠️ Being revised for many indications — ask the prescriber (§14 → med-drug-classes-cardiovascular-anti-infective-and-analgesia) |
| Depression is a chemical imbalance | ⚠️ Oversimplified and unsupported. The drugs still work (§16 → med-drug-classes-neuro-endocrine-immunology-and-oncology) |
| A drug improving a lab value helps you | ⚠️ Surrogate ≠ outcome. See CAST (§13 → med-drug-classes-cardiovascular-anti-infective-and-analgesia, §20 → med-evidence-trials-safety-screening-and-ethics) |
| "Reduces risk 50%" is impressive | ⚠️ Ask for absolute risk and NNT (§20 → med-evidence-trials-safety-screening-and-ethics) |
| Approved means fully characterized | ⚠️ Rare harms appear only post-marketing (§12 → med-pharmacokinetics-pharmacodynamics-and-interactions, §22 → med-evidence-trials-safety-screening-and-ethics) |
| Biosimilars are generics | ⚠️ You can't copy a large protein exactly (§18 → med-drug-classes-neuro-endocrine-immunology-and-oncology) |
| Five-year survival measures progress | ⚠️ Lead time and length bias. Use mortality (§19 → med-drug-classes-neuro-endocrine-immunology-and-oncology, §24 → med-evidence-trials-safety-screening-and-ethics) |
| Early detection is always good | ⚠️ Only if earlier treatment changes outcome (§24 → med-evidence-trials-safety-screening-and-ethics) |
| Overdiagnosis means misdiagnosis | ⚠️ The diagnosis is correct — that's what makes it insidious (§24 → med-evidence-trials-safety-screening-and-ethics) |
| More screening saves more lives | ⚠️ Needs a randomized mortality comparison to know (§24 → med-evidence-trials-safety-screening-and-ethics) |
| Medical error is bad doctors | ⚠️ System failures. Blame destroys reporting (§23 → med-evidence-trials-safety-screening-and-ethics) |
| Healthcare drives life expectancy | ⚠️ Sanitation, nutrition, vaccination did more (§25 → med-evidence-trials-safety-screening-and-ethics) |
| Target the high-risk group | ⚠️ Most cases come from the large modest-risk group (§25 → med-evidence-trials-safety-screening-and-ethics) |
| The antibiotic pipeline is a science problem | ⚠️ A market failure — success means low sales (§27.2) |
§29. Numbers and Concepts
⚠️ ⚠️ PPV depends on PREVALENCE; sensitivity and specificity
do not
⚠️ ⚠️ Worked example ⚠️ 99%/99% test, 1-in-10,000 disease →
⚠️ PPV under 1%
⚠️ Likelihood ratio near 1 ⚠️ the test told you nothing
⚠️ ⚠️ Steady state / washout ⚠️ ~4-5 half-lives
⚠️ Bioavailability ⚠️ IV = 100% by definition
⚠️ Zero-order kinetics ⚠️ ethanol, phenytoin — constant AMOUNT
⚠️ ⚠️ NNT ⚠️ = 1 ÷ absolute risk reduction
⚠️ Wilson-Jungner ⚠️ the treatment criterion is the neglected one
⚠️ ⚠️ Semaglutide obesity trials ⚠️ ~15% mean weight loss
⚠️ ⚠️ Tirzepatide (dual GLP-1/GIP) ⚠️ ~21%
⚠️ Triple agonists in development ⚠️ reported >28%
⚠️ ATTAIN-1 (orforglipron, oral) ⚠️ 11.2%, n=3,127, 72 wk
⚠️ OASIS-4 (oral semaglutide 25mg) ⚠️ 13.6%, n=307, 64 wk
⚠️ ESSENCE (MASH) ⚠️ 62.9% resolution vs 34.3% placebo
⚠️ GLP-1 cardiovascular ⚠️ ~14% MACE reduction
⚠️ ⚠️ AMR ⚠️ ~1 in 6 confirmed bacterial infections resistant
(2023, WHO)
⚠️ GLASS 2025 report ⚠️ >23 million confirmed cases, 104 countries
⚠️ ⚠️ WHO GAP-AMR ⚠️ 2026-2036
⚠️ 2026 AMR Benchmark ⚠️ 25 companies · ⚠️ large-company
pipelines CONTRACTING · SMEs driving priority-pathogen work
§30. Sources
| Source | Why |
|---|---|
| Rang & Dale's Pharmacology; Katzung's Basic & Clinical Pharmacology | ⚠️ §7–§12 → med-pharmacokinetics-pharmacodynamics-and-interactions, the standards |
| Goodman & Gilman's The Pharmacological Basis of Therapeutics | The reference work |
| Guyton & Hall, Textbook of Medical Physiology | §2 → med-reading-the-field-physiology-and-clinical-reasoning |
| Robbins, Pathologic Basis of Disease | §4 → med-reading-the-field-physiology-and-clinical-reasoning |
| Cochrane Library | ⚠️ §20 → med-evidence-trials-safety-screening-and-ethics — systematic reviews, free abstracts |
| BMJ Clinical Evidence tradition; Testing Treatments (free online) | ⚠️ §20–§21 → med-evidence-trials-safety-screening-and-ethics, accessible and excellent |
| Gigerenzer on risk communication | ⚠️ §6 → med-reading-the-field-physiology-and-clinical-reasoning, §20 → med-evidence-trials-safety-screening-and-ethics — natural frequencies fix the base rate error |
| Welch, Should I Be Tested for Cancer? / Overdiagnosed | ⚠️ §24 → med-evidence-trials-safety-screening-and-ethics |
| Rose, The Strategy of Preventive Medicine | ⚠️ §25 → med-evidence-trials-safety-screening-and-ethics — short and foundational |
| WHO fact sheets and GLASS reports | ⚠️ §14 → med-drug-classes-cardiovascular-anti-infective-and-analgesia, §27.2 — primary and free |
| To Err Is Human; Crossing the Quality Chasm | §23 → med-evidence-trials-safety-screening-and-ethics |
| Beauchamp & Childress, Principles of Biomedical Ethics | §26 → med-evidence-trials-safety-screening-and-ethics |
§31. Quick Reference
31.1 Picker
| Question | Where |
|---|---|
| What does my positive test mean? | ⚠️ Ask about pre-test probability first (§6 → med-reading-the-field-physiology-and-clinical-reasoning) |
| Should I get this test? | ⚠️ Will the result change what happens? (§6 → med-reading-the-field-physiology-and-clinical-reasoning, §24 → med-evidence-trials-safety-screening-and-ethics) |
| Is this screening worth it? | ⚠️ Does earlier treatment change mortality? (§24 → med-evidence-trials-safety-screening-and-ethics) |
| How good is this drug? | ⚠️ Absolute risk reduction and NNT, not relative (§20 → med-evidence-trials-safety-screening-and-ethics) |
| Is this trial result trustworthy? | ⚠️ Registered endpoint? ITT? Who funded it? (§21 → med-evidence-trials-safety-screening-and-ethics) |
| Why does this drug take weeks? | ⚠️ Half-lives to steady state, or downstream adaptation (§7 → med-pharmacokinetics-pharmacodynamics-and-interactions, §16 → med-drug-classes-neuro-endocrine-immunology-and-oncology) |
| Can I stop this medication? | ⚠️ Ask the prescriber — some need tapering (§8 → med-pharmacokinetics-pharmacodynamics-and-interactions) |
| Why did the dose change? | ⚠️ Usually renal or hepatic function (§7 → med-pharmacokinetics-pharmacodynamics-and-interactions, §11 → med-pharmacokinetics-pharmacodynamics-and-interactions) |
| Do I need an antibiotic? | ⚠️ Not for viral illness. That's the prescriber's call (§14 → med-drug-classes-cardiovascular-anti-infective-and-analgesia) |
| Is a supplement safe with my meds? | ⚠️ Tell the prescriber. "Natural" means nothing here (§10 → med-pharmacokinetics-pharmacodynamics-and-interactions) |
| Is this survival statistic meaningful? | ⚠️ Five-year survival is biased. Ask for mortality (§19 → med-drug-classes-neuro-endocrine-immunology-and-oncology, §24 → med-evidence-trials-safety-screening-and-ethics) |
| Anything personal or urgent | ⚠️ See a clinician. This file cannot help you (§1 → med-reading-the-field-physiology-and-clinical-reasoning) |
31.2 Evaluating a medical claim
- [ ] ⚠️ Outcome that matters to patients, or a surrogate? (§20 →
med-evidence-trials-safety-screening-and-ethics) - [ ] ⚠️ Absolute risk reduction stated, and NNT? (§20 →
med-evidence-trials-safety-screening-and-ethics) - [ ] ⚠️ Compared against what — placebo, or best current care? (§21 →
med-evidence-trials-safety-screening-and-ethics) - [ ] Randomized, and was allocation concealed? (§21 →
med-evidence-trials-safety-screening-and-ethics) - [ ] ⚠️ Was the endpoint pre-registered, or switched? (§21 →
med-evidence-trials-safety-screening-and-ethics) - [ ] Intention-to-treat analysis? (§21 →
med-evidence-trials-safety-screening-and-ethics) - [ ] ⚠️ Do the trial participants resemble the patient? (§21 →
med-evidence-trials-safety-screening-and-ethics) - [ ] ⚠️ Harms reported as carefully as benefits? (§12 →
med-pharmacokinetics-pharmacodynamics-and-interactions, §20 →med-evidence-trials-safety-screening-and-ethics) - [ ] Who funded it, and who wrote it? (§21 →
med-evidence-trials-safety-screening-and-ethics) - [ ] ⚠️ For a test: what happens to pre-test probability? (§6 →
med-reading-the-field-physiology-and-clinical-reasoning) - [ ] ⚠️ For screening: mortality benefit, and overdiagnosis estimated? (§24 →
med-evidence-trials-safety-screening-and-ethics)
§32. Method
§1–§26 → med-reading-the-field-physiology-and-clinical-reasoning, med-pharmacokinetics-pharmacodynamics-and-interactions, med-drug-classes-cardiovascular-anti-infective-and-analgesia, med-drug-classes-neuro-endocrine-immunology-and-oncology, med-evidence-trials-safety-screening-and-ethics rests on standard preclinical and clinical curricula — ADME, receptor
pharmacology, dose-response, the Bayesian structure of diagnostic testing, the evidence
hierarchy, the documented trial pathologies, Wilson-Jungner, and Rose's prevention
paradox. ⚠️ None needed verification; the pharmacokinetic principles are decades old and
the base rate problem is arithmetic.
⚠️ On scope: I have deliberately included no doses, no regimens and no self-treatment guidance. ⚠️ That is not padding the disclaimer — the concepts here are genuinely useful for evaluating medical claims, and they are useless and dangerous as a substitute for a clinician who knows your history. ⚠️ If something in this file made you think about your own care, the correct next step is a conversation with a clinician, and §31.1 is written to help you have that conversation rather than to replace it.
Two searches were run in August 2026, on incretin therapeutics and antimicrobial resistance — ⚠️ chosen deliberately as a contrasting pair: the fastest-moving area in therapeutics and the slowest, and the contrast between them is itself the lesson about how pharmaceutical incentives allocate effort.
Confidence. High in §6 → med-reading-the-field-physiology-and-clinical-reasoning, which is the section I'd most want read by anyone.
⚠️ The worked example — a 99%/99% test in a 1-in-10,000 population yielding a positive
predictive value under 1% — is arithmetic, not opinion, and it changes how a person reads
every test result they will ever receive. ⚠️ Gigerenzer's finding that presenting this
as NATURAL FREQUENCIES rather than percentages dramatically improves reasoning, including
among clinicians, is why I wrote it out in counts.
⚠️ §24 → med-evidence-trials-safety-screening-and-ethics follows directly from §6 → med-reading-the-field-physiology-and-clinical-reasoning and is where the arithmetic becomes policy — overdiagnosis
is the hardest concept here precisely because the diagnosis is CORRECT, and there is no
constituency for stopping a screening programme.
⚠️ §20 → med-evidence-trials-safety-screening-and-ethics's absolute-versus-relative risk distinction is the most practically useful thing
for reading any health news story.
High on §27.1's trial figures, which come from peer-reviewed publications and phase 3
trial reports: ⚠️ ATTAIN-1's 11.2% in 3,127 adults, OASIS-4's 13.6%, ESSENCE's 62.9%
versus 34.3% for MASH resolution.
⚠️ I have flagged that much accessible coverage comes from pharmacy benefit managers,
discount-card companies and conference reporting — commercially interested sources — and
that §12 → med-pharmacokinetics-pharmacodynamics-and-interactions's rule applies with full force to a drug class adopted this fast.
High on §27.2, anchored on WHO's own fact sheet and GLASS report and on the Access to Medicine Foundation's benchmark — ⚠️ an independent nonprofit rather than an industry body, which is why I used its pipeline finding that large-company pipelines are contracting. ⚠️ The market-failure framing is the part worth carrying: a good antibiotic should be used as little as possible, so the better it is, the less it earns. ⚠️ No other drug class has that property, and it explains why this problem persists while §27.1's does not.
04 同仓库更多 Skills
white-paper-writing
Use when writing white papers, technical reports, policy documents, thought leadership pieces, or any long-form authoritative document. Triggers on requests to write, structure, outline, or review white papers, technical reports, position papers, policy briefs, or evidence-driven arguments. Also use for B2B content marketing strategy, technical documentation requiring authority, academic-style reports, or any document that must educate while persuading. Use when someone asks "how should I structure this" for a long-form document.
prose-technical-mechanics
Use when editing or writing prose at a technical/mechanical level: choosing between Anglo-Saxon and Latinate diction, placing information in topic vs stress positions, writing periodic vs cumulative sentences, handling sentence rhythm, punctuation as logic, transitions, paragraph structure, or phonesthetics. Use when someone wants to understand WHY prose works or doesn't, not just surface-level style advice. Triggers on word choice, sentence structure, emphasis, rhythm, diction, or any deep writing mechanics question.
prose-mechanics
Use when writing, editing, or analyzing prose style; when trying to avoid generic AI-sounding writing; when applying specific prose styles such as journalistic, academic, narrative, KJV biblical, Hemingway plain, Latinate/Jamesian, Orwellian, Augustan, Victorian, Early Modern (Bacon, Browne, Milton), or free indirect discourse; or when coaching someone on writing voice and mechanics. Triggers on any request to improve, analyze, or write in a specific prose style, to fix "AI-sounding" writing, to make prose more vivid or concrete, to vary sentence rhythm, or to understand how a particular writer achieves their effects.
narrative-structure
Use when structuring stories, pitches, presentations, white papers, or any persuasive narrative; analyzing the hero's journey in fiction or non-fiction; applying StoryBrand for business communication; designing narrative arcs for thought leadership; or understanding Vogler, Snyder, Propp, or Campbell frameworks. Triggers on any narrative structure, storytelling, pitch structure, StoryBrand, hero's journey, three-act structure, Freytag, Save the Cat, narrative arc, or "how should I structure this story/pitch/presentation" request.
legal-brief-writing
Use when writing legal briefs, motions, or any court filing; when analyzing judicial cognition and persuasion; when applying elite brief-writing techniques from Roberts, Clement, Kagan, Garner; or when structuring legal arguments for maximum persuasion. Also use for autistic/neurodivergent advocates who need to understand how their natural communication style maps to elite legal advocacy. Triggers on any legal writing, brief drafting, motion preparation, or legal argument structuring request.
journal-publishability-criteria
Use whenever a research paper, article or preprint is being written, revised, reviewed or published, and specifically before every publication of docs/paper.md. Covers what legitimate journals actually gate on, in order of gating — the editor's desk screen (scope, novelty, package problems), what reviewers judge (methodological soundness, claims the evidence can carry, statistical and qualitative reporting), EQUATOR reporting guidelines, the ICMJE authorship criteria, COPE's view of text recycling, the near-universal generative-AI policy (no AI author, disclosure, author responsibility), TOP 2025 transparency standards, how to verify a journal is legitimate, submitting without an institution, and a pre-submission checklist. Triggers on requests to evaluate, review, prepare or submit a paper, to judge publishability, to write a declarations or data-availability section, to disclose AI use, or to check a journal.